Just what is the real risk (of cardiovascular morbidity and mortality for men on ADT)?

So a meta-analysis of data from multiple clinical trials has now shown rigorously something that we did, in fact, already know … that there was no excess incidence of cardiovascular mortality associated with androgen deprivation therapy (ADT) in clinical trials conducted to date in which use of ADT was compared to a placebo. … READ MORE …

EBRT + total (combined) ADT in treatment of high-risk, localized and locally advanced prostate cancer

The big news today is the publication, in The Lancet, of the interim results of the NCIC CTG PR.3/MRC UK PR07 trial, originally presented by Warde et al. at the annual meeting of the American Society for Clinical Oncology in June 2010 and then by Mason et al. at the annual meeting of the American Society for Radiation Oncology (ASTRO) that September. … READ MORE …

Bone mineral density and other risk factors for fractures in men on ADT

Clinical guidelines issued by the National Comprehensive Cancer Network recommend that prostate cancer patients being treated with androgen deprivation therapy (ADT) — either alone or in combination with radiation therapy — should be screened for osteoporosis and treatment to prevent deterioration of bone health associated with a decline in bone mineral density. … READ MORE …

Impact of ADT on all-cause mortality in men treated with brachytherapy-based radiation therapy

The addition of androgen deprivation therapy (ADT) to radiation therapy for men with localized prostate cancer is common. It may be used to reduce the size of the prostate prior to brachytherapy or for longer periods in men with higher risk disease to extend survival (which has been demonstrated in large-scale, randomized, multi-center clinical trials). … READ MORE …

Adjuvant ADT after surgery in men with high-risk prostate cancer

Back in June 2010, we reported on the initial results of SWOG 9921 — a trial that randomized 983 men with high-risk features at prostatectomy to receive adjuvant therapy with androgen deprivation (ADT) alone or in combination with mitoxantrone chemotherapy. … READ MORE …

GTx-758 to enter Phase IIb clinical trial

GTx, Inc. has announced this morning that the company is planning a Phase IIb clinical trial of its oral, selective estrogen receptor agonist (GTx-758, also known as  Capesaris™) as a potential first-line treatment for advanced prostate cancer. … READ MORE …

PSADT and the progression of prostate cancer in men on IADT

Researchers at Johns Hopkins have attempted to correlate data on PSA doubling time (PSADT) with data on prostate cancer progression in men being treated with intermittent androgen deprivation therapy (IADT) after biochemical recurrence of prostate cancer. … READ MORE …